The U.S. Securities & Exchange Commission has hit Puma Biotechnology’s former senior director of regulatory affairs Robert Gadimian with an insider trading…
Boehringer has backed out of the $730 million lung cancer pact it struck with Hanmi Pharmaceutical after reviewing the data and competitive landscape.
Alnylam lost about a half-billion dollars in market cap in trading on the news that it halted development of RNAi liver disease candidate ALN-AAT.
Intra-Cellular Therapies shed about $1.2 billion in market cap on the top-line data on a Phase III trial for its ITI-007 to treat schizophrenia that missed the…
UniQure's CEO has quit after 9 months, Galapagos' CEO quashed Gilead takeover talk, Immunic raised €17.5 million and more.
Gene therapy player bluebird bio has partnered with German biotech Medigene to develop and commercialize T cell receptor (TCR) immunotherapies against four…
Roche’s Genentech is pairing up with Hanmi Pharmaceutical to gain access to its Phase I pan-RAF inhibitor.
Celgene is paying up under a February 2014 deal with Abide Therapeutics to exercise its option for ex-U.S. rights to its only clinical candidate.
Amgen has handed over $56.5 million and committed to up to $617 million more to buy into Arrowhead’s efforts to aim RNAi therapies at cardiovascular targets.
In our EuroBiotech roundup this week, Noxxon lists in Paris, Summit's DMD drug boards the fast track, Bavarian Nordic poaches a CMO from the NCI and more.